Genmab A/S stocks have been fluctuating due to various factors. The company's purchase of
ProfoundBio for $1.8 billion has caused some decline in the stock, but its aggressive
share buyback program progression is a positive sign. This mixed scenario was made more complex as multiple shareholders, including
Wells Fargo & Company MN and
Neuberger Berman Group LLC, offloaded their Genmab stocks. However, other organizations such as
Assetmark Inc. and
Envestnet Portfolio Solutions Inc. have increased their positions. Genmab's Q1 2024 earnings beating both EPS and revenue is another booster for the stock. Despite witnessing a notable price drop and passing below the 200-day moving average, Genmab has seen respectable returns of 82% over the past five years. It performed well in Q1 2024 with strong sales of
DARZALEX and plans for the ProfoundBio takeover. The company has lost an arbitration appeal with Janssen over a drug, possibly causing some investors to become cautious.
Genmab Stocks News Analytics from Fri, 14 Aug 2015 07:00:00 GMT to Sat, 01 Jun 2024 16:15:28 GMT -
Rating -4
- Innovation 0
- Information 4
- Rumor -6
